Southern Shuanglin Bio-Pharmacy halts trading amid control change plans
Southern Shuanglin Bio-Pharmacy announced a trading halt of its shares (SZSE:000403), effective today, June 6, 2025. The suspension is due to ongoing planning regarding a potential change in control of the company. According to the announcement, the major shareholder, Gongqingcheng Shengbang Yinghao Investment Partnership (Limited Partnership) is planning matters relating to the change in control. The company anticipates the trading halt will not exceed two trading days. Southern Shuanglin Bio-Pharmacy advises investors to be aware of potential investment risks due to the uncertainty surrounding the change of control. The company will disclose further information through official announcements in the Securities Times and on the CNINFO website.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Southern Shuanglin Bio-Pharmacy publishes news
Free account required • Unsubscribe anytime